Evaxion Biotech A/S
NASDAQ:EVAX
Intrinsic Value
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. [ Read More ]
The intrinsic value of one EVAX stock under the Base Case scenario is 172.2855 USD. Compared to the current market price of 4.2071 USD, Evaxion Biotech A/S is Undervalued by 98%.
Fundamental Analysis
Balance Sheet Decomposition
Evaxion Biotech A/S
Current Assets | 8.4m |
Cash & Short-Term Investments | 5.6m |
Receivables | 815k |
Other Current Assets | 2m |
Non-Current Assets | 4.5m |
PP&E | 4.3m |
Other Non-Current Assets | 196k |
Current Liabilities | 7.1m |
Accounts Payable | 2.7m |
Other Current Liabilities | 4.4m |
Non-Current Liabilities | 10.5m |
Long-Term Debt | 10.4m |
Other Non-Current Liabilities | 149k |
Earnings Waterfall
Evaxion Biotech A/S
Revenue
|
73k
USD
|
Operating Expenses
|
-22.3m
USD
|
Operating Income
|
-22.2m
USD
|
Other Expenses
|
72k
USD
|
Net Income
|
-22.1m
USD
|
Free Cash Flow Analysis
Evaxion Biotech A/S
EVAX Profitability Score
Profitability Due Diligence
Evaxion Biotech A/S's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Evaxion Biotech A/S's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
EVAX Solvency Score
Solvency Due Diligence
Evaxion Biotech A/S's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Evaxion Biotech A/S's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EVAX Price Targets Summary
Evaxion Biotech A/S
According to Wall Street analysts, the average 1-year price target for EVAX is 11.985 USD with a low forecast of 7.07 USD and a high forecast of 18.9 USD.
Shareholder Return
EVAX Price
Evaxion Biotech A/S
Average Annual Return | -58.11% |
Standard Deviation of Annual Returns | 5.52% |
Max Drawdown | -96% |
Market Capitalization | 20.2m USD |
Shares Outstanding | 4 811 560 |
Percentage of Shares Shorted | 1.18% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.